Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Evolus sells aesthetic injectables — a wrinkle-smoothing neurotoxin and hyaluronic acid gels — to people who pay out of their own pocket.
Evolus sells a shot that smooths out frown lines between the eyebrows. That product, called Jeuveau, is a botulinum toxin — the same basic kind of molecule as Botox — and it is aimed at people who want to look fresher without surgery. The company's customers are regular people, not insurers or hospitals, so every sale is cash paid directly at a doctor's office or clinic. It also sells Evolysse, a line of hyaluronic acid gels used as dermal fillers, which the company began launching in the United States in 2025. Both products sit squarely in the "medical aesthetics" market: quick, in-office treatments that people choose and pay for themselves.
The economics are unusual and worth understanding. Evolus does not discover these molecules from scratch. Jeuveau was developed by a partner, and the company's real job is getting it into clinics, training injectors, building a brand, and persuading consumers to ask for it by name. That means heavy spending on sales reps and marketing. The upside is that a vial of neurotoxin is cheap to make and sells for a lot, so once the sales force is paid for, extra revenue drops through at high margins. The catch is that this is a fight for shelf space and injector loyalty against much bigger players. That is the core risk. The aesthetics market is dominated by AbbVie, whose Botox is the household name and the default choice for many clinics, and by other toxin makers fighting for the same faces. Evolus tries to stand out on price, on a "no bruising" marketing pitch, and on loyalty programs that reward clinics for sticking with it. It also carries a heavy debt load and has spent years burning cash to grow, which makes profitability a work in progress rather than a given. The 2025 addition of Evolysse matters because it gives injectors a second reason to deal with Evolus — a filler to sell alongside the toxin — and a shot at growing revenue per customer.
The company is based in Newport Beach, California, and its story has a colorful edge: it was founded by people with roots in the aesthetics business and later tangled with AbbVie in a legal fight over trade secrets, which it settled. The interesting question for investors is simple. Can a smaller challenger build a real brand in a market where the leader is a household name, and can it do that fast enough to outrun its debt and finally turn a profit? Jeuveau's growth and the Evolysse rollout are the two things to watch.
Saved answer · last researched 15 Nov 2026